Filing Flows › Pfizer (PFE) › Q2 2026 › vs Q1 2026
Pfizer (PFE) Q2 2026 vs Q1 2026 (quarter over quarter)
Pfizer's revenue rose $583M (+4%) from $14.5B in Q1 2026 to $15.0B in Q2 2026.
Pfizer, Q2 2026: revenue $15.0B (+3% year over year), operating margin -4.3%, net loss $237M, operating cash flow $835M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.0% | 15.1% | -13.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $15.0B | $14.5B | $583M | +4% |
| Income tax benefit | $407M | −$461M | $868M | — |
| Net loss | $237M | −$2.7B | $2.9B | — |
| Costs & expenses | $15.7B | $14.5B | $1.2B | +8% |
| Operating costs | $15.7B | $11.3B | $4.4B | +39% |
| Cost of revenue | $4.1B | $3.5B | $544M | +15% |
| Research & development | $2.8B | $2.5B | $319M | +13% |
| SG&A | $3.4B | $3.0B | $450M | +15% |
| Other operating costs | $5.4B | $2.3B | $3.1B | +134% |
| Operating cash sources | $1.9B | $1.9B | −$14.0M | -0.7% |
| Depreciation & amortization | $1.6B | $1.6B | $9.0M | +0.6% |
| Share-based compensation | $249M | $272M | −$23.0M | -8% |
| Net loss absorbed | $237M | −$2.7B | $2.9B | — |
| Working capital & other | $799M | $2.0B | −$1.2B | -59% |
| Operating cash flow | $835M | $2.6B | −$1.8B | -68% |
| Free cash flow (OCF − capex) | $302M | $2.2B | −$1.9B | -86% |
| Capital expenditures | $533M | $436M | $97.0M | +22% |
Questions
How much did Pfizer's revenue grow quarter over quarter in Q2 2026?
Pfizer's revenue rose $583M (+4%) from $14.5B in Q1 2026 to $15.0B in Q2 2026.